SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Price & Overview
NASDAQ:SNSE • US81728A2078
Current stock price
The current stock price of SNSE is 30.57 USD. Today SNSE is down by -3.08%. In the past month the price increased by 13.95%. In the past year, price increased by 271.76%.
SNSE Key Statistics
- Market Cap
- 40.964M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -16.67
- Dividend Yield
- N/A
SNSE Stock Performance
SNSE Stock Chart
SNSE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SNSE. When comparing the yearly performance of all stocks, SNSE is one of the better performing stocks in the market, outperforming 98.85% of all stocks.
SNSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNSE. SNSE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNSE Earnings
SNSE Forecast & Estimates
6 analysts have analysed SNSE and the average price target is 33.15 USD. This implies a price increase of 8.44% is expected in the next year compared to the current price of 30.57.
SNSE Groups
Sector & Classification
SNSE Financial Highlights
Over the last trailing twelve months SNSE reported a non-GAAP Earnings per Share(EPS) of -16.67. The EPS increased by 30.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.07% | ||
| ROE | -113.41% | ||
| Debt/Equity | 0 |
SNSE Ownership
SNSE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 349.118B | ||
| AMGN | AMGEN INC | 15.03 | 183.592B | ||
| GILD | GILEAD SCIENCES INC | 14.64 | 158.566B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.13 | 108.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 78.702B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.05 | 41.165B | ||
| INSM | INSMED INC | N/A | 29.351B | ||
| NTRA | NATERA INC | N/A | 28.968B | ||
| BIIB | BIOGEN INC | 11.32 | 26.515B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.093B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.46 | 24.851B | ||
| MRNA | MODERNA INC | N/A | 19.314B | ||
| INCY | INCYTE CORP | 12.18 | 19.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNSE
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Company Info
IPO: 2021-02-04
SENSEI BIOTHERAPEUTICS INC
1405 Research Blvd, Suite 125
Rockville MARYLAND 20850 US
CEO: John Celebi
Employees: 15
Phone: 18008998648
SENSEI BIOTHERAPEUTICS INC / SNSE FAQ
Can you describe the business of SENSEI BIOTHERAPEUTICS INC?
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
What is the stock price of SENSEI BIOTHERAPEUTICS INC today?
The current stock price of SNSE is 30.57 USD. The price decreased by -3.08% in the last trading session.
What is the dividend status of SENSEI BIOTHERAPEUTICS INC?
SNSE does not pay a dividend.
How is the ChartMill rating for SENSEI BIOTHERAPEUTICS INC?
SNSE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for SENSEI BIOTHERAPEUTICS INC?
SENSEI BIOTHERAPEUTICS INC (SNSE) currently has 15 employees.
What is the market capitalization of SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) has a market capitalization of 40.96M USD. This makes SNSE a Nano Cap stock.
What is the Short Interest ratio of SENSEI BIOTHERAPEUTICS INC (SNSE) stock?
The outstanding short interest for SENSEI BIOTHERAPEUTICS INC (SNSE) is 91.04% of its float.